IGFBP2 and breast cancer: However, considering the significant validation tests related to nonhubs (nodes with lower K, BC), including NID2, MXRA5, FKBP10, SULF1, THY1, AEBP1, TGM2, CDH17, CDH6, TGIF1, IGFBP2, and PAPPA, we hypothesize that these nodes can be associated with hubs and have the potential to be GC biomarkers.